Ed Dybka

Biography

Ed Dybka is the President of AstraZeneca Canada Inc., part of AstraZeneca PLC, one of the world’s leading biopharmaceutical companies. Mr. Dybka has more than 25 years of experience in the Canadian pharmaceutical industry.  In 2012, he led the Canadian establishment of Almirall, a start-up biopharmaceutical company focused on the treatment of respiratory diseases and affiliated with Almirall S.A., with headquarters in Barcelona, Spain. Prior to establishing Almirall in Canada, Mr. Dybka held a number of executive roles at GlaxoSmithKline Canada from 2004 to 2012, including Vice President of Marketing, Sales and Public Affairs & Reimbursement.  During this time, he was accountable for the marketing and sales of all GSK pharmaceutical products, including specialty care, oncology and vaccines, achieving strong commercial performance and employee engagement.  Earlier in his career, Mr. Dybka held progressively senior roles in product management and product development, as well as sales, at Glaxo Wellcome Canada Inc. and Zeneca Pharma Inc. Mr. Dybka is currently a Director on the Board of Life Sciences Ontario, an organization that represents and promotes the province's vibrant and diverse life sciences sector.  He has served on a number of other Boards, including the George Hull Centre for Children and Families, the Pharmaceutical Advertising and Advisory Board, the Canadian Pharmaceutical Distribution Network, and The Mississauga Board of Trade. Mr. Dybka holds a Bachelor of Science degree in Toxicology from the University of Toronto. He lives in Toronto with his wife and two children. AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.  AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. AstraZeneca’s Canadian headquarters are located in Mississauga, Ontario.

Research Interest

Global innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.